SCHEMBL342740

SCHEMBL342740

Cc1ccc(OBOc2ccccc2C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44
HTR2A P28223 2/20 0.38
SLC6A4 P31645 2/20 0.38
MAPT P10636 1/20 0.37
TSHR P16473 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ACHE P22303 2/20 0.37
LMNA P02545 1/20 0.37
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
TDP1 Q9NUW8 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5842048 0.88 DRD2 (0.41) DRD2DRD4DRD3HTR2ASLC6A4
SCHEMBL9270 0.85 TSHR (0.46) SLC6A4TSHRSMN1; SMN2NPC1RAB9A
SCHEMBL177637 0.81 ACHE (0.52) DRD2DRD4DRD3MAPTTSHR
SCHEMBL5841039 0.77 CA12 (0.41) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL172615 0.75 HTR2A (0.55) DRD2DRD4DRD3HTR2ASLC6A4
SCHEMBL28604976 0.74 HTR2A (0.53) DRD2DRD4DRD3HTR2ASLC6A4
SCHEMBL2310163 0.72 ALDH1A1 (0.41) DRD2DRD4DRD3HTR2ASLC6A4
SCHEMBL27819241 0.71 DRD2 (0.45) DRD2DRD4DRD3HTR2ASLC6A4
SCHEMBL27819167 0.71 DRD2 (0.45) DRD2DRD4DRD3HTR2ASLC6A4
SCHEMBL363120 0.71 ACHE (0.52) DRD2DRD4DRD3RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3140007-A1 METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF Apicore US LLC (US) 2017-03-15 EP claimed
US-20160368875-A1 METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF MYLAN API US LLC 2016-12-22 US claimed
WO-2015171489-A1 METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF APICORE US LLC (US) 2015-11-12 WO claimed
US-20150315149-A1 METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF MYLAN API US LLC 2015-11-05 US claimed
US-8921299-B2 Detergents having acceptable color THE PROCTER & GAMBLE COMPANY (US) 2014-12-30 US claimed
US-20260109131-A1 CROSS-LINKED POLYVINYL ALCOHOL ADHESIVES PROCTER & GAMBLE (US) 2026-04-23 US disclosed
US-20260110139-A1 CROSS-LINKED POLYVINYL ALCOHOL ADHESIVES PROCTER & GAMBLE (US) 2026-04-23 US disclosed
EP-4638687-A2 DETERGENT COMPOSITION COMPRISING CATALASE AND AMYLASE Novozymes A/S (DK) 2025-10-29 EP disclosed
EP-4634219-A1 HIGH STRENGTH LIQUID PROTEASE FORMULATIONS Novozymes A/S (DK) 2025-10-22 EP disclosed
US-20250295120-A1 CLEANING METHOD, USE OF ENZYMES AND CLEANING COMPOSITION NOVOZYMES A/S (DK) 2025-09-25 US disclosed
US-20250129307-A1 Microencapsulation Using Amino Sugar Oligomers NOVOZYMES A/S (DK) 2025-04-24 US disclosed
WO-2025073833-A1 OPTIMIZED PROCESS FOR THE PREPARATION OF IOPAMIDOL BRACCO IMAGING SPA (IT) 2025-04-10 WO disclosed
EP-1144388-A1 ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS Elan Pharmaceuticals, Inc. (US) 2001-10-17 EP disclosed
WO-2000043372-A1 ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS ELAN PHARMACEUTICALS, INC. (US) 2000-07-27 WO disclosed
US-5880188-A PROTECTING MEDIUM SUSCEPTIBLE TO MICROBIAL ATTACK BY TREATING WITH SPECIFIED OXABOROLE COMPOUND ZENECA LIMITED (GB) 1999-03-09 US disclosed
EP-0873123-A4 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 1999-02-03 EP disclosed
EP-0873123-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-10-28 EP disclosed
WO-1997017070-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1997-05-15 WO disclosed
EP-0765331-A1 OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES ZENECA LIMITED (GB) 1997-04-02 EP disclosed
WO-1995033754-A1 OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES ZENECA LIMITED (GB) 1995-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368875-A1 METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF NMUR1, NNT, NMUR2 DRD2 1441/4885DRD4 1570/4885DRD3 1852/4885
US-20250295120-A1 CLEANING METHOD, USE OF ENZYMES AND CLEANING COMPOSITION DNASE1, HEXD, HEXA DRD2 1959/4885DRD4 1665/4885DRD3 2278/4885
US-20260109131-A1 CROSS-LINKED POLYVINYL ALCOHOL ADHESIVES VCAM1, PLOD3, TLN1 DRD2 2315/4885DRD4 2357/4885DRD3 2283/4885
US-20150315149-A1 METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF NMUR1, NNT, NMUR2 DRD2 1441/4885DRD4 1570/4885DRD3 1852/4885
US-20260110139-A1 CROSS-LINKED POLYVINYL ALCOHOL ADHESIVES VCL, PLOD3, ILK DRD2 2837/4885DRD4 3034/4885DRD3 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.